

Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma

Information for the public

Published: 13 June 2018

www.nice.org.uk

Brentuximab vedotin (Adcetris) is available on the NHS as a possible treatment for relapsed and refractory CD30-positive Hodgkin lymphoma in adults who:

- have already had a stem cell transplant using their own cells or
- cannot have multi-agent chemotherapy or a stem cell transplant using their own cells, but have already had at least 2 other treatments.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS website](#) may be a good place to find out more. These organisations can give you advice and support:

- [Macmillan Cancer Support](#), 0808 808 00 00
- [Cancer Research UK patient information](#) (previously CancerHelp UK), 0808 800 4040
- [Bloodwise](#) (previously Leukaemia & Lymphoma Research), 0808 2080 888
- [Lymphoma Action](#) (previously Lymphoma Association), 0808 808 5555
- [Leukaemia CARE](#), 08088 010 444

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-2965-8